Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'

Executive Summary

Other sponsors could be using tactics other than REMS abuse to game the system, US FDA Commissioner Scott Gottlieb says.

You may also be interested in...



FDA Lifts Future REMS Burden On Antiretroviral Leaders

As generics of Gilead’s Truvada combination antiretroviral reach the US market, their manufacturers will no longer have to provide risk-mitigation education.

US Ambrisentan Approvals Hint At Different Commercial Approaches

Four different firms have simultaneously received FDA approval for ambrisentan generics of Gilead’s Letairis. But different safety programs suggest Zydus Pharma may be taking a different commercial approach to the other three generics firms.

REMS Website Will Name, Not Shame, Potential Abusers – Gottlieb

US FDA will list number of inquiries about acquiring samples for generic drug development, and also whether FDA sends letters to brand companies telling them it is safe to provide the generic sponsor with the samples. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB002420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel